2013—biotech back in the saddle

Last year's biotech stocks substantially outperformed the general markets, with the BioCentury 100 and NASDAQ Biotechnology indices showing >25% gains over the S&P 500 and NASDAQ Composite. Excluding partnership monies, a total of $36.7 billion was raised, on par with 2012. The first IPO window since 2007 brought in $3.8 billion, up 168% from 2012; follow-on offerings ($10 billion) were also up 58% from 2012; but debt deals were down from 2012's $19.6 billion. Private company fundraising came in at around the 2008–2012 annual average of $5.5 billion.

Stock market performance

Global biotech industry financing

Global biotechnology venture capital investment

Global biotech initial public offerings

Notable 2013 deals

Box 1: Stock market performance

For 2013, the BioCentury 100 gained 59%, while the NASDAQ Biotechnology Index was up 66%.

Box 2: Global biotech industry financing

Excluding partnerships, biotechs raised $36.7 billion in 2013, compared with $36.6 billion in 2012.

Box 3: Global biotechnology venture capital investment

Private biotechs raised $5.7 billion in 2013, down from $6.6 billion in 2012.

Box 4: Notable 2013 deals

Box 5: Global biotech initial public offerings

59 companies raised $3.8 billion via IPOs in 2013 compared with the 2008–2012 annual average of $963 million.